RenovoRx

RenovoRx is a developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. RenovoRx received FDA clearance for the RenovoCath™ RC120 and is currently introducing this innovative technology to the clinical market.

RenovoRx has a motivated Management Team with broad experience and an exciting vision for the future of targeted delivery. The company also has a broad Advisory Board of interventional radiologists, surgical oncologists and gastroenterologists that guide the company's clinical development strategies. RenovoRx is backed by a strong Board of Directors committed to long-term, continuous support of the company, whose members provide critical expertise in the medical and biotechnology industry and the visionary thinking to succeed.

RenovoRx headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical Device, Therapeutics sector. The company focuses on Biotechnology and has secured $5.2B in funding across 160 round(s). With a team of 1-10 employees, RenovoRx is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - RenovoRx, raised $660.0K. Discover more about their projects, partnerships, and impact on our platform.